- Home
- PHAR vs ACIC Comparison
PHAR vs ACIC Comparison
Compare PHAR & ACIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ACIC
- Stock Information
- Founded
- PHAR 1988
- ACIC 1999
- Country
- PHAR Netherlands
- ACIC United States
- Employees
- PHAR N/A
- ACIC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ACIC Property-Casualty Insurers
- Sector
- PHAR Health Care
- ACIC Finance
- Exchange
- PHAR Nasdaq
- ACIC Nasdaq
- Market Cap
- PHAR 731.1M
- ACIC 556.0M
- IPO Year
- PHAR N/A
- ACIC N/A
- Fundamental
- Price
- PHAR $10.00
- ACIC $10.77
- Analyst Decision
- PHAR Strong Buy
- ACIC Buy
- Analyst Count
- PHAR 3
- ACIC 1
- Target Price
- PHAR $30.00
- ACIC $16.00
- AVG Volume (30 Days)
- PHAR 3.6K
- ACIC 236.5K
- Earning Date
- PHAR 07-31-2025
- ACIC 08-06-2025
- Dividend Yield
- PHAR N/A
- ACIC 4.60%
- EPS Growth
- PHAR N/A
- ACIC 3.21
- EPS
- PHAR N/A
- ACIC 1.49
- Revenue
- PHAR $320,708,000.00
- ACIC $302,261,000.00
- Revenue This Year
- PHAR $13.31
- ACIC N/A
- Revenue Next Year
- PHAR $7.68
- ACIC $37.63
- P/E Ratio
- PHAR N/A
- ACIC $7.38
- Revenue Growth
- PHAR 24.13
- ACIC 23.92
- 52 Week Low
- PHAR $6.65
- ACIC $8.82
- 52 Week High
- PHAR $12.61
- ACIC $15.08
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- ACIC 47.93
- Support Level
- PHAR $9.99
- ACIC $10.64
- Resistance Level
- PHAR $10.59
- ACIC $11.16
- Average True Range (ATR)
- PHAR 0.35
- ACIC 0.26
- MACD
- PHAR -0.14
- ACIC 0.04
- Stochastic Oscillator
- PHAR 7.45
- ACIC 51.58
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.